share_log

Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63

Benzinga ·  Dec 8, 2023 05:29

Baird analyst Brian Skorney initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform rating and announces Price Target of $63.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment